secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001437749-24-025027
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology wins patent suit vs AstraZeneca; $107.5M jury award upheld in bench trial
--------------------------------------------------------------------------------

- Jury found Tagrisso infringes Wyeth's patents; damages of $107.5M for past infringement through Dec 31, 2023.
- Bench trial on equitable claims ruled in Wyeth's favor; all AstraZeneca defenses rejected.
- Puma maintains contractual rights to recover monetary damages under license with Pfizer.
- Post-trial motions pending; AstraZeneca seeks new trial, Wyeth seeks supplemental damages and ongoing royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924025027/0001437749-24-025027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924025027/pbyi20240806_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-025027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer